Introduction
Gliomas of astrocytic, oligodendrogial and ependymal origin are the most common primary brain tumors in humans, with nearly 15 000 diagnosed annually in the United States (1) . In the last decades, China witnessed a rapid increase in the incidence of malignant brain tumors. In 2000, the annual incidence of cerebral tumors was ,3.9 per 100 000 in men and 2.8 per 100 000 in women among Chinese population (2) . Despite the development of novel drugs and therapeutics in the last 5 years, the average survival for the patients with glioblastoma (GBM), the most malignant gliomas [World Health Organization (WHO) grade IV], is 14 months after diagnosis (3) . Hence, identification of epidemiological factors that influence development of gliomas would facilitate its prevention or early detection and subsequently provides better prognosis. High-dosage ionizing irradiation is a well-established risk factor of gliomas (4) , but only a small proportion of individuals exposed to ionizing irradiation will develop gliomas. Therefore, hereditary factors are generally believed to contribute to the development of gliomas (5, 6) . Until now, however, there have been few validated genetic markers associated with glioma risk.
Two genome-wide association studies among the populations of European descent have identified two single nucleotide polymorphisms (SNPs), rs6010620 and rs2297440, in 20q13.33 (RTEL1), which were significantly associated with glioma risk (7, 8) . Of two risky loci, rs6010620 has been confirmed to be related to glioma risk in a Chinese Han population in our previous replication study (9) . Two recent genome-wide association studies also identified their susceptibility loci at 20q13.33 for Crohn's disease (10) and atopic dermatitis (11) . Interestingly, the genes in this region regulate some important genes like epidermal growth factor receptor, FASLG and GLUT4 which participate in many cell processes that highly correlated with tumor development, including proliferation, apoptosis, the transport and uptake of glucose. To identify other genetic variants which could contribute to the risk of glioma development in the region of 20q13.33, a fine mapping study consisting of 983 cases and 1024 controls was performed in a Chinese Han population from eastern China.
Materials and methods

Study population
The subject enrollment method has been described elsewhere (9, 12) . In brief, 983 patients histopathologically diagnosed with gliomas and 1024 healthy controls from the Department of Neurosurgery at Huashan Hospital, Fudan University between October 2004 and July 2009 were recruited in this study. There were no restrictions on age, sex and histology; however, the patients with a self-reported history of cancer and previously receiving radiotherapy and chemotherapy for unknown disease conditions were excluded. Also, pathological diagnoses and demographic data of all eligible cases were validated by trained abstractors. All control subjects were randomly selected from trauma outpatients and annual checkup visitors at the same hospital during the similar time period and frequency matched to cases by sex, age (±5 years) and residence (urban or rural areas). Those with central nervous system-related diseases, a self-reported history of cancer or a history of radiotherapy/ chemotherapy were excluded. No evidence of demographic differences was observed between two subtypes of controls. All cases and controls in this study were genetically unrelated Han Chinese from Shanghai and its surrounding regions (Jiangsu, Anhui and Zhejiang provinces) in eastern China.
At recruitment, written informed consent was obtained from each subject and each participant was then interviewed by a trained nurse to collect detailed information, including demographic factors, smoking status, occupational radiation exposure, family history of cancer and other lifestyle factors. For childhood glioma patients under the age of 18 years, baseline data were collected from their parents. After interview, $3-5 ml peripheral venous blood sample was collected from each subject for DNA extraction and genotyping. The research protocol was approved by the Ethics Committee for Human Subject Research of Fudan University.
Selection of tagging SNPs and genotyping assays
The region of 20q13.33 (62291000-62387830, GRCh37.p5) which spanned $100 kb and contained six genes, RTEL1, TNFRSF6B, adenosine diphosphate ribosylation factor-related protein 1 (ARFRP1), ZGPAT, SLC2A4RG and ZBTB46, was opted for this fine mapping analysis. A total of 13 tagging SNPs in this region were selected based on the Chinese Han population in HapMap Phase 2 data with the criteria of minor allele frequency !0.05 and r 2 !0.8. Seven of 13 SNPs were located in RTEL1, in which rs2297440 had a strong linkage disequilibrium (LD) with rs6010620 (D# 5 1, r 2 5 1) in the HapMap Chinese Han population data. Two SNPs were in ARFRP1. One SNP was in ZGPAT. The other one, rs1058319, was in the 3#untranslated region of SLC2A4RG. The last two SNPs were in ZBTB46, one of which, rs5019252, was a synonymous mutation in exon 5, E568E.
Human genomic DNA was isolated from whole-blood samples using the Qiagen Blood Kit (Qiagen, Chatsworth, CA), according to the manufacturer's instructions. After extraction, genomic DNA was diluted to a final concentration Abbreviations: CI, confidence interval; GBM, glioblastoma; HWE, Hardy-Weinberg equilibrium; LD, linkage disequilibrium; OR, odds ratio; SNP, single nucleotide polymorphism.
Ó The Author 2012. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com of 15-20 ng/ll for the genotyping assays. Fragments containing polymorphisms were amplified by the PCR and genotyped with Sequenom MassARRAY iPLEX platform using allele-specific matrix-assisted laser desorption ionizationtime-of-flight mass spectrometry assay (13) . Primers for amplification and extension reactions were designed using MassARRAY Assay Design Version 3.1 software (Sequenom, San Diego, CA). SNP genotypes were obtained according to the iPLEX protocol provided by Sequenom. Laboratory personnel who assessed all genotyping results were blinded to the case-control status. Genotyping quality was examined by a detailed quality control procedure consisting of over 95% successful call rate, duplicate calling of genotypes, internal positive control samples and Hardy-Weinberg equilibrium (HWE) testing.
Imputation and statistical analysis
To better represent the variants of 20q13.33, we imputed the SNPs in this region which was analyzed based on the genotyped SNPs and haplotype information in the 1000 Genomes Project (http://mathgen.stats.ox.ac.uk/impute/data_down-load_1000G_phase1_integrated.html) using a computer program, IMPUTE2 (http://mathgen.stats.ox.ac.uk/impute/impute_v2.html) (14) . GTOOL software (http://www.well.ox.ac.uk/$cfreeman/software/gwas/gtool.html) was used to transform the imputed data from GEN to PED format. A posterior probability of 0.9 was used as a threshold to call genotypes. PLINK software (http:// pngu.mgh.harvard.edu/$purcell/plink/) (15) was performed to select SNPs with minor allele frequency !0.05 and genotyping rate !0.9 and then to analyze the HWE and genotype frequencies of SNPs both imputed and genotyped between cases and controls and their association with glioma risk. The independence of glioma associations with SNPs at 20q13.33 was tested (assuming an additive model at each SNP) in a logistic regression model. Odds ratio (OR) and 95% confidence intervals (CIs) were calculated using unconditional logistic regression adjusted for the potential glioma risk factors, including age, sex and family history of cancer.
Cumulation test was performed to evaluate the effect of the risk alleles, which were independent susceptibility loci for glioma, by counting the number of risk alleles per individual.
SPSS software (SPSS, Chicago, IL) was used for statistical analyses of genotyped SNPs, unless indicated otherwise. All P-values presented were two-sided, and a level of P ,0.05 was considered statistically significant.
LD was assessed by the Haploview software V4.2 (http://www. broad.mit. edu/mpg/haploview) using the method given by Gabriel et al. (16) . To assess the association between inferred haplotypes and risk of gliomas, analytical approaches implemented in the software package Haplo.stats (http:// www.mayo.edu/hsr/Sfunc.html) were used. The software employs an expectation-maximization algorithm to infer haplotypes from the observed genotypes with an unknown linkage phase. To account for haplotype ambiguity, the probability for each haplotype pair was assigned to each individual, which was used to model individual phenotypes as a function of the estimated probability. The statistical significance of the performed global-and haplotypespecific tests (haplo.score) was expressed as a permutation P-value (minimal simulation: 10 000 with a significance level ,0.05) (17) .
Results
Sample characteristics
To carry out this fine mapping study, 983 cases and 1024 controls were recruited from eastern China. The distribution of demographic variables among glioma cases and controls was shown in Table I . The histological subtypes were also presented. Among all cases, 369 (37.6%) were astrocytoma and 306 (31.1%) were GBM and 303 (30.8%) suffered from other types of carcinoma (including oligodendrogliomas, ependymomas or mixed glioma). Overall, age and sex were adequately matched between cases and controls (P 5 0.98 and 0.55, respectively). The mean age was 42.19 ± 15.77 years for cases and 42.21 ± 18.63 years for controls. Approximately 60% subjects were male in both cases and controls. There were comparable never-, ever-and current smokers between cases (59.7, 20.7 and 18.7%, respectively) and controls (58.8, 21.2 and 19.0%, respectively; P 5 0.92), but a significant difference regarding family history of cancer was found between cases and controls (P 5 4.00 Â 10 À3 ).
Single-SNP analysis
To explore whether additional SNPs in the regions flanking SNP rs2297440 are associated with glioma risk, we genotyped 13 tagging SNPs in $100 kb genomic region at 20q13.33 in a Chinese Han population. The information of 13 genotyped SNPs was detailed in Table II . The 13 markers were located in a $100 kb region containing six genes (RTEL1, TNFRSF6B ARFRP1, ZGPAT, SLC2A4RG and ZBTB46) ( Figure 1 ). The genotyping rate of 13 SNPs was .95% and all 13 SNPs were in HWE in control subjects (P . 0.01). To reduce the potential of spurious findings due to multiple testing, P 5 7.69 Â 10 À4 (0.01/13) was considered as significance threshold using strict Bonferroni corrections. Eight of 13 locus were significantly associated with the risk of glioma, and two SNPs (rs2257885, P 5 1.77 Â 10 À9 and rs1058319, P 5 2.22 Â 10 À11 ) satisfied the threshold for genome-wide significance (P , 10 À8 ). Half of the eight SNPs (rs6089953, rs6062484, rs3787098 and rs2297440) were located in RTEL1, and the other four markers (rs2257885, rs3761121, rs1058319 and rs5019252) were in ARFRP1, ZGPAT, SLC2A4RG and ZBTB46, respectively.
To improve the density of variants within the region of 20q13.33, we imputed the SNPs in this region based on the genotyped SNPs and haplotype information in the 1000 Genomes Project using a computer program, IMPUTE2. Ninety-nine SNPs, both genotyped and imputed were obtained and used for subsequent analysis. All 99 loci were in HWE in control subjects (P . 0.01), and 55 SNPs were significantly associated with glioma risk after strict Bonferroni corrections (P , 1 Â 10 À4 ; Supplementary Table S1 is available at Carcinogenesis Online).
The independence of glioma associations with SNPs at 20q13.33 was tested (assuming an additive model at each SNP) in a logistic regression model from the 55 significant SNPs. We identified five independent SNPs to be significantly associated with glioma risk using multilocus models. Multivariate logistic regression analyses revealed that after the adjustment for age, sex and family history of cancer, compared with wild-type carriers, all these five loci significantly increased the glioma risk (adjusted OR 5 1.65 and 95% CI 5 1. (Table III) .
Further stratified analyses of five independent loci were carried out between low-grade astrocytoma and GBM (Table IV) . We found that one SNP, 20-62315594, was more evident in GBM risk compared with wild-type genotype GG (adjusted OR 5 2.23, 95% CI 5 1.66-2.99 and P-value 5 1.23 Â 10 À7 for GT/TT), but no significant associations were found in astrocytoma risk after adjusting for age, sex and family history of cancer (adjusted OR 5 1.27, 95% CI 5 0.97-1.67 and P 5 0.08 for GT/TT). The remaining four SNPs were significantly associated with the risk of both astrocytoma and GBM.
Cumulation analysis
To understand the cumulative effects of these variants on glioma risk, we established a variable to combine the effects of risk alleles per individual from the five independently risk SNPs (20-62315594, 20-62335293, rs3761121, rs1058319 and rs5019252). Overall, glioma risk increased with the increase of the number of risk alleles (P trend 5 1.94 Â 10 À11 , adjusted OR 5 1.43, 95% CI 5 1.29-1.58). Individuals carrying 7-10 risk alleles had a 2.64-fold higher risk of developing glioma compared with those who carried zero risk alleles (adjusted OR 5 2.64, 95% CI 5 1.79-3.88, P-value 5 8.71 Â 10 À7 ; Table V) .
Haplotype analysis
Haplotype blocks were determined by the haploview software (http:// www.broad.mit.edu/mpg) using the method given by Gabriel et al. (16) . Three blocks were identified in this region using 13 genotyped SNPs (Supplementary Figure S1 is available at Carcinogenesis Online). The global score test showed significant differences in haplotype frequency distribution between the cases and controls for all the three blocks (Supplementary Table S2 is available at Carcinogenesis Online).
Further stratified analysis of three blocks showed that only block 3 was significantly associated with the risk of astrocytoma. All three blocks were significantly associated with GBM (Supplementary  Table S3 is available at Carcinogenesis Online). The results of haplotypes were consistent with single-SNP analysis. No novel markers were identified.
Discussion
In this fine mapping analysis, 13 genotyped and 86 imputed SNPs were used to investigate the association with glioma risk among 983 cases and 1024 controls recruited from eastern China. We confirmed five independent risk-associated SNPs at 20q13.33. The first SNP, 20-62315594, maps to intron 13 of RTEL1 (regulator of telomere elongation helicase 1), is in the same LD block with the original SNP (rs2297440). RTEL1 is a DNA helicase critical for regulation of telomere length in mice and is associated with shortened telomere length, chromosome breaks and translocations (18) and it maintains genomic stability directly by suppressing homologous recombination (19) . Rs2297440 and rs6010620 were identified from two genomewide association studies (7, 8) and had a strong LD (D# 5 1 and r 2 5 1) in Chinese Han population data of HapMap. Our previous replication study also confirmed rs6010620 was significantly associated with glioma risk in Chinese Han population (9) . These combined studies of showed similar results that the P-value of allele frequency was at 10 À6 level. Wrensch et al. (8) identified that rs6010620 was associated with susceptibility for high-grade glioma, however, Egan et al. (20) pointed out that the SNPs of RTEL1 were associated with both low-and high-grade astrocytic tumors. In this study, significant association was only observed between GBM risk and the SNPs of RTEL1 except rs3208008. The similar result that rs6010620 was highly correlated with high-grade glioma was confirmed in a cohort study from France and Germany (21) . The differences of ethics and/or gene-environment interactions may account for the discrepant results. Although rs3208008 was located in RTEL1 gene, it had a strong LD (D# 5 1 and r 2 5 1 in Chinese Han population in HapMap data) with rs2257885, which was located in ARFRP1. Rs3208008 is a missense polymorphism (Gln1042His) in exon 32 of RTEL1 and localizes to the C-terminal of RTEL1 protein. This glutamine-to-histidine exchange may change the structure of RTEL1 protein, and hence, alter its function. In this study, rs3208008 significantly correlates with the risk for both astrocytoma and GBM, which is consistent with what Egan et al. (20) had found. So RTEL1 may play complex roles in glioma development among the populations of different origins.
The second independent locus, 20-62335293, which is intronic to ARFRP1, is the most significant SNP in a region of RTEL1-TNFRSF6B-ARFRP1. Tumor necrosis factor receptor superfamily, member 6b, decoy (TNFRSF6B), also known as Decoy receptor 3, was identified to bind to CD95L and block cell death induced by CD95L (22) . The expression of TNFRSF6B correlates with glioma grade and mainly overexpressed in GBM (23) . Our results also showed that the variants in TNFRSF6B were only highly correlated with GBM risk. ARFRP1 is a member of the ARF family (24) and recruits a second guanosine triphosphatase, ARL1, and its effector the Golgin-97, RanBP2a, Imh1p, and P230/golgin-245 (GRIP) protein golgin-245 to the trans-Golgi network (25, 26) . Knockout of ARFRP1 The significant differences are indicated in bold.
a Adjusted for sex, age and family history of cancer. Fine mapping at 20q13.33 and risk of glioma in mice was lethal (27) . The deletion of the guanosine triphosphatase ARFRP1 severely altered GLUT4 sorting as well as Golgi structures, but the status of ARFRP1 could not change GLUT4 expression (28) . ARFRP1 is ubiquitously expressed in many tissues, such as skeletal muscle, fat, liver, kidney, brain and so on (24, 29) . The relationships between variants and ARFRP1 and their association with glioma risk need further investigation to validate. The third independent locus, rs1058319, is located in the 3#un-translated region of SLC2A4RG and is the most significant SNP in this study. Rs1058319 is 46 bp far away from stop codon. Using PupaSuite, an interactive web-based SNP analysis tool (http:// pupasuite.bioinfo.cipf.es/), we found that rs1058319 was an exonic splicing enhancer. We also predicted the microRNA around rs1058319 using TargetScanHuman 6.0 (http://www.targetscan.org/) and found the locus rs1058319 located at a target of miR-491-5p. The region surrounding rs1058319 plays an important role in regulating the expression of SLC2A4RG. The expression of SLC2A4RG shows a 2.17-fold increase in GBM compared with that expressed in normal tissue in The Cancer Genome Atlas database. SLC2A4RG, also known as GEF, is an enhancer factor of SLC2A4 (GLUT4, the solute carrier family 2 member 4 gene). GLUT4 is one member of the family of glucose transport proteins and plays a key role in cellular glucose uptake mediated by both insulin and insulin-like growth factor-1 (30, 31) . It has been known that one of the most fundamental characteristics of cancer cells development is increased levels of glucose uptake despite reduced levels of oxygen consumption (32) . In astrocytic tumor cells, the facilitative glucose transport had been altered (33) . This may be a reason for glioma development. Meanwhile, SLC2A4RG, as a transcription factor, was also identified to bind to neuronal cell-specific cis-regulatory element in the promoter for the human Huntington's disease gene (34) . The overexpression of SLC2A4RG may play an important role in the development of glioma.
The fourth independent locus, rs3761121, located in intron 3 of ZGPAT (also known ZIP), is a transcription repressor and negatively regulates the expression of epidermal growth factor receptor, a gene involved in cell proliferation, survival, migration and overexpression in glioma (35) . The ZIP depletion leads to a drastic tumor growth in vivo (36) .
The last independent locus, rs5019252, maps to exon 5 of ZBTB46, is a synonymous mutation. Compared with the original codon GAG, the translation efficiency of synonymous codon GAA decreased by 30% according to the prediction by a website software, Graphical Codon Usage Analyser (http://gcua.schoedl.de/). ZBTB46, a zinc finger and BR-C, ttk and bab (BTB) domain containing 46, also known as RINZF, is a transcription factor, which coexpresses with Sp1 seemingly to block the activating effects of Sp1 mediated through the CACC element of the gastrin promoter (37) . Few reports focusing upon this gene have been conducted.
Previous studies of copy number variants identify large fragments amplificated in chromosome 20 in GBM (38, 39) . The region of 20q13.33 also shows amplification in $30% of glioma (7) . Data of the Memorial Sloan-Kettering Cancer Center indicate that the copy number variants of six genes (RTEL1, TNFRSF6B, ARFRP1, ZGPAT, SLC2A4RG and ZBTB46) in this study are altered in glioma (http:// cbio.mskcc.org/cancergenomics/gbm/cna/).
To sum up, we fine-mapped the 20q13.33 region surrounding the original SNPs, rs2297440, and indicated that the region exerts a complex effect by the independent signals contributing to glioma risk. Of the 13 SNPs directly genotyped in the region of 20q13.33, two SNPs showed the genome-wide significance (P-value , 10 À8 ) in association with glioma risk. Unconditional analyses using multilocus models identified five independent loci: 20-62315594, 20-62335293, rs3761121, rs1058319 and rs5019252. The first locus, 20-62315594, is in a strong LD with the original SNP, rs2297440. The second locus, 20-62335293, is in a strong LD with a marker previously reported, rs3208008, and the other three loci are novel risk SNPs which have never been reported previously. Overall, the region of 20q13.33 contains several important genes which participated in many cell processes, which are related to development of tumor including proliferation, apoptosis and glucose transport and uptake. We have identified a set of variants in 20q13.33 significantly associated with glioma risk, which may provide a novel insight into glioma development. Both variants and genes should be considered in further studies to elucidate the molecular basis of the relationship between 20q13.33 and glioma susceptibility.
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